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To identify DNA copy number changes that had a direct influence on mRNA expression in gastric cancer, cDNA microarray-based
comparative genomic hybridization (aCGH) and gene expression profiling were performed using 17 K cDNA microarrays. A set of 158 genes
showing Pearson correlation coefficients over 0.6 between DNA copy number changes and mRNA expression level variations was selected. In an
independent gene expression profiling of 60 tissue samples, the 158 genes were able to distinguish most of the normal and tumor tissues in an
unsupervised hierarchical clustering, suggesting that the differential expression patterns displayed by this specific group of genes are most likely
based on the gene copy number changes. Furthermore, 43 statistically significant (P<0.01) genes were selected that correctly distinguished all of
the tissue samples. The copy number changes detected by aCGH can be verified by fluorescence in situ hybridization and real-time polymerase
chain reaction. The selected genes include those that were previously identified as being tumor suppressors or deleted in various tumors, including
GATA binding protein 4 (GATA4), monoamine oxidase A (MAOA), cyclin C (CCNC), and oncogenes including malignant fibrous histiocytoma
amplified sequence 1 (MFHAS1/MASL1), high mobility group AT-hook 2 (HMGA2), PPAR binding protein (PPARBP), growth factor receptor-
bound protein 7 (GRB7), and TBC1 (tre-2, BUB2, cdc16) domain family, member 1 (TBC1D1).
© 2006 Elsevier Inc. All rights reserved.Keywords: Gastric cancer; aCGH; Expression profiling; cDNA microarray; Comparative genomic hybridization; Real-time polymerase chain reaction; Oncogene;
Tumor suppressorIntroduction
Gastric cancer is the second most common cause of cancer-
related mortalities [1]. Even though progress is being made in
the field of gastric cancer treatment, curative surgery remains
the most effective option [2,3]. Unfortunately, gastric cancer is
usually diagnosed at an advanced stage and the prognosis for
treatment at that time is poor [4]. Understanding gastric cancer
at a molecular level could contribute to the development of
diagnostics and/or therapeutics.⁎ Corresponding author. Department of Internal Medicine, Yonsei University
College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752,
South Korea.
E-mail address: unchung8@yumc.yonsei.ac.kr (H.C. Chung).
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doi:10.1016/j.ygeno.2006.12.001Information about DNA copy number changes can be
obtained at a single-gene resolution using cDNA microarray-
based comparative genomic hybridization (aCGH) [5,6] and
this technique has been applied to gastric cancer to define the
novel regions of chromosomal amplification [7]. A gene copy
number change is likely biologically more meaningful if it is
directly related to a change in gene expression. Despite the
vast amount of genome-scale analysis of DNA copy number
changes and expression profiling in gastric cancer, informa-
tion about the relationship between copy number changes and
gene expression changes is limited, except for a few cases
[7–10].
In this study, in an effort to identify genes that show a
correlated pattern of variation in DNA copy number and gene
expression in gastric cancer, gene copy number changes were
452 S. Yang et al. / Genomics 89 (2007) 451–459first identified using 30 pairs of gastric tissues and the aCGH
technique. Correlations between DNA copy number changes
and expression level variations were calculated for a common set
of genes identified from aCGH and gene expression profiling.
Validation of the gene copy number changes was obtained using
fluorescence in situ hybridization (FISH). An independent set of
gene expression profiling measurements was also used to
validate the selection of genes showing a differential expression
pattern due to DNA copy number changes.
Results
DNA copy number changes in gastric cancer
When the pattern of DNA copy number changes detected by
aCGH was visualized as a function of the nucleotide position
of genes, changes were observed on all of the chromosomes
(Fig. 1A). This is consistent with results from a recent BAC
array CGH analysis of gastric cancer, which also showed that
all the chromosomes except 21 and Y underwent copy number
changes [11].
To analyze the frequency of copy number changes, the
genome-wide localization of copy number-changed genesFig. 1. (A) Stem plot of edge-preserving smoother for the pattern of gene copy numbe
edge-preserving smoother (see reference [12] for a detailed description of a smoot
changes. Selection of copy change was based on 4% of altered genes averaged over a
averaged over all aberrant genes. The false discovery rate was kept to 0.selected by the analysis of copy errors (ACE) algorithm was
examined (Fig. 1B). Noticeably, chromosomes 20, 8, and X
contained more genes undergoing frequent copy number
changes, whereas the high-frequency gene deletions were
observed on chromosomes Y, 4, 6, and 18.
In addition, a search was performed for genes that
displayed a 1.5-fold (log2 ratio of 0.58) increase or decrease
in tumor samples (Cy5) compared to normal tissue (Cy3).
Overall, 1780 gene copy number increases and 376 copy
number decreases were detected (Supplementary Table 1).
Several of the genes that were previously reported as having
alterations in copy number in gastric cancer were identified
in the current analysis, including catenin beta 1 (CTNNB1)
[12], v-erb-b2 erythroblastic leukemia viral oncogene
homolog 2 (ERBB2/HER-2) [10,13,14], dual-specificity
tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2),
protein tyrosine kinase 7 (PTK7) [7], v-myc myelocyto-
matosis viral oncogene homolog (avian) (MYC) [15,16],
fibroblast growth factor receptor 2 (FGFR2) [17], nuclear
receptor coactivator 3 (NCOA3/AIB1) [18], growth factor
receptor-bound protein 7 (GRB7) [19], and LIM homeobox
1 (LHX1) [9]. The copy number changes for other genes,
including aurora kinases, p53, DCC and APC, were notr changes. A scatter plot of the data along with a curve fitted to the data using an
hing algorithm used for CGH-Explorer). (B) Frequency of gene copy number
ll arrays and 8% of the number of arrays displaying a particular gene aberration,
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microarrays used in the current experiments.
The correlation between DNA copy number changes and
mRNA expression
One of the biological implications of a copy number change
of a gene in vivo would be the accompanying changes in the
amount of mRNA synthesized from that gene. To probe how the
DNA copy number changes in gastric cancer affect expression
levels of those genes, expression profiling was performed using
a subset (n=12) of tissues used in the aCGH in a direct
comparison (tumor Cy5 versus normal Cy3) experiment.
Pearson correlation coefficients were calculated for each of the
1436 commonly selected genes from the aCGH and expression
profiling data. A group of 158 genes had Pearson correlation
coefficients greater than 0.6 (Fig. 2A). Two of the genes showing
a high correlation were HER-2 and GRB7 (Fig. 2B).
Validation of the selection of correlated pattern of gene copy
number changes and mRNA expression from independent gene
expression profiling data
The selection of 158 genes that showed correlated patterns of
variations in DNA copy number and expression level was based
on direct-design experiments (normal Cy3 versus tumor Cy5) of
aCGH and expression profiling. Genes showing correlatedFig. 2. Genes showing correlated patterns of change in DNA copy number and mRN
range. (B) Examples of genes showing a high correlation between gene copy nu
coefficients of 0.997 and 0.983, respectively.variations in copy number and gene expression level in tumor
tissue compared with normal gastric tissue would be expected to
show a differential gene expression pattern between the two
groups. This can be tested in a gene expression profiling set,
performed using a reference RNA-based indirect experiment, in
which the gene expression levels from tumor and normal tissues
can be compared in parallel.
To utilize this technique, an independent set of samples was
prepared (n=60, gastric tissue RNA Cy5 versus reference RNA
Cy3). An unsupervised two-way (genes and samples) hierarch-
ical clustering of the 60 tissues based on the 158 genes
identified from the previous experiments showed that the two
groups were well distinguished, except for three tumor samples
that clustered closer to the normal group (Fig. 3A). Application
of a two-sample t-test to the 158 genes and 60 tissues identified
a smaller, statistically significant set of 43 genes (P<0.01) that
could correctly distinguish all of the tissue samples (Fig. 3B and
ratio data in Table 1) in a supervised two-way hierarchical
clustering. These are the genes showing differential gene
expression between gastric tumor tissues and normal gastric
tissues and the main mechanism for this specific differential
expression is most likely DNA copy number change. These
include genes functioning in basic functions such as the cell
cycle (SMC1, CCNC, CDC6), transcription (POLR1C, TAF15,
GATA4, GATA6), sugar metabolism (PMM1), amino acid
metabolism (MAOA), signal transduction (TLR1), and DNA
replication (RPA3).A level. (A) Number of genes that belong to each Pearson correlation coefficient
mber change and mRNA expression. HER-2 and GRB7 showed correlation
Fig. 3. Clustering of an independent set of expression profiling data from 60
tissue samples with genes showing high correlation between DNA copy number
changes and variations in gene expression levels. (A) An unsupervised
hierarchical clustering of 60 tissues with 158 genes showing Pearson correlation
coefficients over 0.6 between DNA copy number change and mRNA expression
variation. (B) Hierarchical clustering of 60 tissues with 43 genes that were
selected via a t-test (P<0.01) from 158 genes shown in A, with information on
GenBank ID numbers and gene symbols. Ratio scale bar for the Treeview color
change is also shown. The TST gene location in Treeview is shown with an
arrow for ease of navigation. The Cy5/Cy3 ratios of the 43 genes from aCGH
and expression profiling are detailed in Table 1 in the order in which the genes
are shown in B.
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situ hybridization and real-time polymerase chain reaction
(RT-PCR)
One of the genes that showed a high level of copy number
changes was HER-2. HER-2 showed copy number increases in
two tissues (Tissues No. 1189G3 and No. 296G3) out of 30 cases
tested (a frequency of 6.6%). Two independent cDNA copies of
HER-2 clones were printed on the microarrays and both showed
similar Cy5/Cy3 ratios in the two tissues. One clone
(AW057736) showed log2(Cy5/Cy3) ratios of 1.92 (Tissue
No. 1189G3) and 2.05 (Tissue No. 296G3), and the other clone
(AA446928) showed log2(Cy5/Cy3) ratios of 2.35 (Tissue No.
1189G3) and 2.53 (Tissue No. 296G3). These two tissues (No.
1189G3 and No. 296G3), together with nine other tissues with
varying HER-2 log2(Cy5/Cy3) ratios, were subjected to FISH
analysis with HER-2 probes (Supplementary Fig. 1). The exact
two tissues, No. 1189G3 and No. 296G3, in which aCGH
initially identified HER-2 DNA copy number increases showed
high-level HER-2 copy number increases in FISH, validating
the measurement of DNA copy number changes using aCGH.
Real-time polymerase chain reaction was also employed in
an effort to quantitatively measure the relative copy number
changes (Fig. 4). When the relative amount of PCR product was
measured for the genes whose log2(Cy5/Cy3) ratios range from
0.03 (GATA6) to 0.59 (PGM2) in absolute number, the ΔΔCt
[difference of normalized threshold cycle (Ct) values of a gene
in normal tissue and tumor tissue threshold cycle] values close
to 1 (a twofold change) was sought. PGM2 and COPS6, which
had log2(Cy5/Cy3) ratios of ­0.59 and 0.57, showed ΔΔCt
values of ­1.06 and 1.02, respectively, at least in one
experiment each.
Discussion
In this study, we performed a genome-wide analysis of DNA
copy number changes in gastric cancer, by way of aCGH, using
30 pairs of gastric tissues on 17 K cDNA microarrays.
In deciding the Cy5/Cy3 ratios that define copy number
changes, the log ratios of 0.58 and ­0.58 were selected
because the values that are within this range were observed in
a normal:normal hybridization experiment and therefore were
considered signal noise. This cannot be an absolute standard
for a copy change. To be more quantitative, we tried a RT-
PCR for exons of genes on genomic DNA substrate. In three
RT-PCRs, an average ΔΔCt value that corresponds to log2
(Cy5/Cy3) was less than 1.0. This means that aCGH
overestimated the copy changes that might happen in vivo.
However, in the FISH reaction, HER-2, which had log2(Cy5/
Cy3) ratios of ∼2 and should represent less than 10 copies, in
fact, showed more than 30 copies. In this sense, aCGH
underestimated the real copy changes. Also, DMD2, which
had a log2(Cy5/Cy3) ratio of 0.39, showed a ΔΔCt close to 1
in one of the experiments. We plan to use aCGH as an initial
screening tool for the selection of copy number-changed genes
and employ other molecular tools for the exact quantitation of
the individual genes.Several of the genes previously shown to have alterations in
copy number were also identified in the current study, including
CTNNB1, HER-2, DYRK2, PTK7, MYC, FGFR2, NCOA3,
GRB7, LHX1, and YES1. DYRK2 and GRB7 showed copy
number increases at frequencies of 33.3 and 23.3%, respec-
tively. Lower frequencies were observed for the other genes
such as NCOA3 (20%), CTNNB1 (16.7%), FGFR2 (6.6%),
HER-2 (6.6%), PTK7, MYC, LHX1, and YES1 (3.3%
frequency). In contrast, novel genes showing a higher frequency
of DNA copy number changes, including supervillin (SVIL),
Fig. 3 (continued ).
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(Supplementary Table 1). The gene copy number changes were
able to distinguish the patients based on the intestinal and
diffused histological subtypes. A statistically significant group
of 10 genes was selected (P<0.01). However, a two-way
hierarchical clustering did not clearly distinguish the two groups
of samples (see Supplementary Information).
To extract biological meaning from the large number of
genes undergoing copy number changes in our analysis, we
focused on those genes that showed correlated patterns between
copy number change and gene expression. This was accom-
plished by performing an additional set of genome-wide gene
expression profiling measurements in a direct design and
calculating the Pearson correlation coefficients between the
aCGH and expression profiling results for each gene. A set of
158 genes was selected from this combined analysis.
The selection of the genes that show a high correlation
between copy number and expression changes is expected, in
principle, to enrich for those that are differentially expressed
between normal gastric tissues and gastric tumor tissues. That
expectation is realized when the group of 158 genes was used to
cluster 30 pairs of normal gastric tissues and tumor tissues in an
independent, common reference-based (an indirect design) geneexpression profiling experiment. All of the tissues were
correctly clustered into either a tumor tissue or a normal gastric
tissue group based on the gene expression profiles of the 158
genes, except for three tumor tissues that were remotely
clustered into the group of normal gastric tissues in an
unsupervised two-way hierarchical clustering (Fig. 3A). This
unsupervised clustering result strongly supports the idea that the
158 genes show differential expression patterns between the
two groups and that the underlying molecular basis for this
differential expression is the differential gene copy number
changes, which were initially identified by aCGH. Subse-
quently, a two-sample t-test was used to select a smaller set of
genes that could perfectly distinguish the two groups (Fig. 3B
and Table 1). For example, HER-2 and GRB7 are two of the
genes showing a high Pearson correlation coefficient (Fig. 2),
but only the expression level of GRB7 is significantly different
between the two groups (Fig. 3B). Use of this method does not
downplay the fact that HER-2 shows DNA copy number
increases and also shows correlated gene expression. On the
contrary, HER-2 showed the highest correlation coefficient
(∼0.997) between DNA copy number changes and gene
expression. In addition, both HER-2 and GRB7 were among
the 158 genes that were able to distinguish most of the normal
Table 1
aCGH and expression ratios, frequency, and correlation coefficients for 43 genes showing a high degree of correlation between copy change and mRNA expression
GenBank ID No. Name Symbol Gene expression aCGH C.C.
Normal Tumor Ratio Frequency
AI688589 Calcium/calmodulin-dependent serine protein kinase CASK 0.88 1.18 1.67 1 0.76
AA677340 Phosphorylase kinase, alpha 2 PHKA2 0.87 1.19 1.73 1 0.78
AI016468 CCAAT/enhancer binding protein (C/EBP), gamma CEBPG 0.95 1.37 1.63 7 0.62
AA453404 PPAR binding protein PPARBP 0.93 1.30 2.79 2 0.79
H53703 Growth factor receptor-bound protein 7 GRB7 0.81 1.82 4.86 2 0.98
AI366964 Ankyrin repeat domain 11 ANKRD11 0.97 1.35 0.65 1 0.68
AA481603 Formin binding protein 3 FNBP3 0.86 1.19 1.54 1 0.62
AA599120 TSC22 domain family, member 1 TGFB1I4 0.89 1.34 2.89 1 0.99
AI681049 Malignant fibrous histiocytoma amplified sequence 1 MFHAS1 0.84 1.44 1.75 1 0.69
AI017696 McKusick-Kaufman syndrome MKKS 0.89 1.43 2.31 1 0.77
AI017797 Malignant fibrous histiocytoma amplified sequence 1 MFHAS1 0.88 1.52 2.55 1 0.70
AA009738 MYB binding protein (P160) 1a MYBBP1A 0.91 1.18 2.06 1 0.91
AI279844 ATP binding cassette, subfamily C, member 10 ABCC10 0.91 1.23 1.95 1 0.99
AW070763 Structural maintenance of chromosomes 1-like 1 SMC1L1 0.84 1.18 1.58 1 0.62
AA427818 High mobility group AT-hook 2 HMGA2 0.80 2.13 1.69 1 0.75
AI337373 PHD finger protein 19 PHF19 0.71 1.58 1.74 9 0.64
AA406020 Interferon, alpha-inducible protein (clone IFI-15K) G1P2 0.78 1.79 1.54 1 0.83
AI000313 Selenoprotein H SELH 0.85 1.19 1.52 1 0.77
AA598988 Ubiquitin-specific peptidase 39 USP39 0.85 1.20 1.83 1 0.64
AA992441 COP9 constitutive photomorphogenic homologue subunit 6 COPS6 0.88 1.19 1.56 1 0.73
AA704613 MYC-associated zinc finger protein MAZ 0.86 1.43 0.64 1 0.73
AA872690 Chaperonin containing TCP1, subunit 6A CCT6A 0.84 1.41 1.57 1 0.77
AA733038 Polymerase (RNA) I polypeptide C, 30 kDa POLR1C 0.81 1.77 2.20 2 0.97
H59259 Replication protein A3, 16 kDa RPA3 0.85 1.21 1.64 3 0.74
H59204 CDC6 cell division cycle 6 homologue CDC6 0.70 1.86 5.24 1 0.72
AI261346 TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 TBC1D1 0.81 1.33 1.56 2 0.61
AA857343 TBP-associated factor, 68 kDa TAF15 0.86 1.35 1.61 2 0.80
AA598640 Midline 1 MID1 0.86 1.15 0.58 1 0.62
AA910836 Ankylosis, progressive homologue (mouse) ANKH 0.92 1.38 1.58 1 0.79
AA969816 Phosphoglucomutase 2 PGM2 0.87 1.21 2.24 3 0.80
AA432063 Thiosulfate sulfurtransferase (rhodanese) TST 1.06 0.68 1.71 1 0.60
AA451686 Cyclin C CCNC 1.11 0.78 0.65 1 0.71
AI339155 Toll-like receptor 1 TLR1 1.11 0.77 1.96 1 0.61
AA190825 Tumor necrosis factor, alpha-induced protein 8 TNFAIP8 1.11 0.64 1.67 1 0.61
AA699926 Syntrophin, alpha 1 SNTA1 1.22 0.75 2.02 16 0.64
AA459012 Chromosome 6 open reading frame 209 C6orf209 1.20 0.76 0.62 1 0.63
AA011096 Monoamine oxidase A MAOA 1.68 0.43 1.60 1 0.64
AA872728 Nuclear receptor subfamily 2, group F, member 6 NR2F6 1.13 0.77 1.63 6 0.66
H77652 GATA binding protein 6 GATA6 1.31 0.49 6.19 1 0.98
AA431347 GATA binding protein 4 GATA4 1.38 0.34 2.06 1 0.87
AA026152 SEC22 vesicle trafficking protein-like 3 SEC22L3 1.13 0.78 1.60 1 0.72
AI521155 G protein-coupled receptor 64 GPR64 1.60 0.62 1.79 2 0.78
AA461118 Dystrophin DMD 1.35 0.76 0.63 1 0.62
Note. The genes are listed from the top in the order shown in the Treeview image in Fig. 3B. Gene expression refers to Cy5/Cy3 ratios from indirect gene expression
profiling shown in Fig. 3B. Normal and Tumor refer to an average Cy5/Cy3 of 30 samples from normal tissue and tumor tissue, respectively. aCGH ratio refers to an
average Cy5/Cy3 ratio for only those cases (Frequency) in which the ratio is over 1.5-fold changed [log2(Cy5/Cy3)≥0.58 or <−0.58]. The C.C. (Pearson correlation
coefficient) is measured between microarray CGH and gene expression profiling performed in a direct design for a subset of 12 pairs of tissues. Information on the full
names and symbols for the genes was obtained from SOURCE (http://genome-www5.stanford.edu/cgi-bin/source/sourceSearch).
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hierarchical clustering (data not shown). Here, the emphasis
in selecting the 43 genes was a high standard of statistical
measure applied (P<0.01).
One of the key mechanisms leading to the activation of
oncogenes and the inactivation of tumor suppressor genes is
gene copy number changes [20], as has been shown in cases
such as HER-2 and MYC in gastric cancer [9,21]. In this sense,
it is important to note that several of the 43 identified genes were
previously reported as being deleted or being tumor suppressorcandidates in different diseases. For example, GATA4 mRNA
synthesis is diminished in ovarian [22] and gastric cancer [23]
and the GATA4 gene, located at 8p23.1–p22, is in one of the
two regions, 8p23.2–8p22 and 8p21.3–8p11.22, that are
frequently deleted in colorectal cancer [24]. These facts led to
the proposal that GATA4 was a potential tumor suppressor [25].
Likewise, MAOA [26] and CCNC [27] have been reported as
being deleted in patients with Norrie disease and in acute
lymphoblastic leukemia, respectively. Several of the 43 genes
are also candidate oncogenes or highly homologous to known
Fig. 4. Validation of copy changes by real-time PCR. Normal and tumor genomic DNAs from patient 1125 were used to quantitate the amplification product of
exons of five genes. In the table, aCGH and RT-PCR refer to log2(Cy5/Cy3) ratios and ΔΔCt values, respectively. For example, ΔΔCt for PGM2 refers to a
(ΔCt normal PGM2­ΔCt normal actin)­(ΔCt tumor PGM2­ΔCt tumor actin). N.D., not done.
457S. Yang et al. / Genomics 89 (2007) 451–459oncogenes. MFHAS1/MASL1 is a candidate oncogene [28] and
a truncated form of HMGA2 displays oncogenic activities both
in vivo and in vitro [29]. PPARBP and GRB7 were shown to be
amplified and overexpressed in different tumors [30,31].
TBC1D1 is homologous to the TRE-2 oncogene [32].
Gastric cancer is currently being dissected at the molecular
level with genomic and proteomic tools to draw novel
molecular signatures that could be helpful in early diagnosis
or treatment [11,33–37]. Our study is a contribution to these
collective efforts and specifically provides a list of candidate
oncogenes and tumor suppressors that could help to elucidate
gastric cancer at the molecular level.
Materials and methods
Gastric cancer tissues and aCGH
All experiments using patient tissues were performed after gaining the
approval of the supervisory committee of the Yonsei University College of
Medicine. Only tissues from patients who underwent surgery at the Yonsei
University College of Medicine (1997–1999) and who were followed for at least
5 years after surgery were used. Tissues with at least 70% tumor content,
confirmed by a pathologist (W.I. Yang), were saved as the tumor tissues. A pair
of tissues refers to a normal gastric mucosa sample and a tumor tissue sample
obtained from the same patient. Thirty pairs of normal and tumor gastric tissues
used in these experiments were ground to a powder and the genomic DNAwas
prepared using the phenol/chloroform/isoamylalcohol method [38].
Human cDNA microarrays (GenomicTree, Daejeon, Korea) were manu-
factured using 17,000 clones spotted by an OmniGrid Microarrayer (Gene-
Machines, Inc., San Carlos, CA) onto a silanized glass slide surface (CMT-
GAPS, Corning, Charlotte, NC). These 17,000 clones (Ultimate ORF Clones,
Resgen/Invitrogen, Carlsbad, CA) were full-insert sequenced and a 100% match
to known amino acid sequences was confirmed. Of these, approximately 10,000were function-annotated clones and the rest were CGAP clones, the molecular
functions of which have not yet been fully characterized. The cDNAmicroarrays
were used for both aCGH and expression profiling.
Six micrograms of DpnII-digested genomic DNA was purified using a
QIAquick PCR purification kit (QIAgen, Düsseldorf, Germany) and was
subjected to fluorescence labeling using a Bioprime labeling kit (Invitrogen,
Carlsbad, CA). The reaction mixtures were incubated at 37°C for 2 h in the dark
and were quenched by adding 5 μl of 0.5 M EDTA, pH 8.0. The microarray slide
was incubated in 3.5×SSC, 0.1% SDS with 10 mg/ml BSA for 1 h at 42°C for
blocking. The genomic DNA from the normal and tumor tissues was labeled
with Cy3-dCTP and Cy5-dCTP, respectively. Cy3- and Cy5-labeled DNA from
the tissue sample was mixed with 30 μg human Cot-1 DNA, 20 μg poly(dA)–
poly(dT) oligonucleotides, and 100 μg yeast tRNA. A Microcon-30 filter
(Amicon, Bedford, MA) was used to purify and concentrate the hybridization
mixture, which was then adjusted to a final concentration of 3.5×SSC and 0.3%
SDS in a volume of 60 μl. Following denaturation at 100°C for 1.5 min and pre-
annealing at 37°C for 30 min, the labeled DNA mixture was applied to the
cDNA microarray and incubated at 65°C for 20–30 h. The slide was then
washed for 2 min each in 0.5×SSC/0.01% SDS, 0.06×SSC/0.01% SDS, and
0.05×SSC, consecutively, at room temperature and spin-dried. The microarray
slides were scanned using a GenePix 4000B scanner (Axon Instruments, Foster
City, CA) and the data were saved in a Gene Pix Result (GPR) format. The
microarray data have been deposited in the ArrayExpress database (http://www.
ebi.ac.uk/arrayexpress/#ae-main[0]).
aCGH analysis
For visualization and detection of copy number alteration (CNA), the ACE
algorithm in the CGH-Explorer was employed [39]. For this purpose, start and
end information for each gene was obtained from NCBI build 35 and the
midpoint was used as a “nucleotide position” in the CGH-Explorer. Of the
17,067 probes printed on the microarray, probes were removed from the analysis
if the foreground intensities were not 1.5-fold higher than the background
intensities. Also only those that had reliable “start–end” information for the
genes (10,548 genes) in NCBI build 35 were used for the analysis. Cy5/Cy3
ratios were converted into log2-transformed values and the arrays were mean-
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information for the genes on each chromosome. The missing values (<20%)
were imputed with the array mean.
Correlation between aCGH and gene expression profiling
Twelve of the 30 pairs of tissues were used for gene expression profiling in
an experiment designed to match the experimental design employed in aCGH.
Total RNA preparation, hybridization, scanning, and normalizations were
performed following a previously published protocol [40]. GPRs were imported
into GeneSpring 7.2 (Agilent, Palo Alto, CA) and intensity-dependent “loess
normalization” was applied to the data set to adjust for discrepancies in labeling
efficiencies. Reliable spots were filtered using a cross-gene error model function
(removes low-control Cy3 intensity spots) in GeneSpring 7.2 for further
analysis. The analysis of CNA by CGH-Explorer, or any of the similar programs
freely available, showed that it did not distinguish genes that showed a mixed
pattern of variation, such as the same genes showing a DNA copy number
increase in some of the patients and a decrease in other patients. Therefore, for
the correlation analysis between copy number change and expression variation,
the copy number change was considered an increase when log2(Cy5/Cy3) was
over 0.58 (∼1.5-fold increase in a tumor tissue compared with a normal
counterpart) and a decrease when log2(Cy5/Cy3) was less than −0.58. The log
ratios of 0.58 and −0.58 were selected because the values that are within this
range were observed in a normal:normal hybridization experiment and therefore
were considered signal noise [41]. Clones with independent GenBank ID
numbers were considered individual genes. Overall, 2156 genes showed copy
number variations at least once when the 1.5-fold standard was used. A common
set of 1436 genes was extracted from filtered genes in the gene expression
profiling data and 2156 genes that were defined as having alterations in DNA
copy number. Pearson correlation coefficients between DNA copy number
changes and variations in mRNA expression levels for each gene were
calculated in Microsoft Excel. A set of genes with Pearson correlation
coefficients over 0.6 was selected.
Independent set of gene expression profiling
Sixty additional gene expression profiling experiments were performed in a
common reference RNA-based indirect comparison experiment to compare the
gene expression pattern from normal and tumor tissues in parallel. These were
independent of the samples used for aCGH and the direct-comparison profiling
mentioned above. The tissue samples consisted of 30 pairs of normal and tumor
tissues, of which 16 pairs (1 pair with tumor grade II, 7 pairs with grade III, and
8 pairs with grade IV) had a history of recurrence and the other 14 pairs (1 pair
with grade II, 5 pairs with grade III, and 8 pairs with grade IV) had no history of
recurrence. GPRs were imported into GeneSpring 7.2 and fluorescence ratios
were loess-normalized. Genes with Pearson correlation coefficients of greater
than 0.6 (n=158) were used for an unsupervised hierarchical clustering of 60
cases of normal and tumor samples. Of these genes, a statistically significant set
of genes was further selected using a two-sample t-test at P<0.01. Clustering
and Treeview visualization were performed in GeneSpring.
Fluorescence in situ hybridization
The HER-2 probe was a mixture of a spectrum green fluorophore-labeled α-
satellite DNA probe for chromosome 17 (17p11.1–q11.1) and a spectrum
orange fluorophore-labeled DNA probe for the HER-2 gene locus (17q11.2–
q12) (Vysis PathVysion HER-2 DNA Probe Kit; Vysis, Downers Grove, IL).
HER-2 and chromosome 17 nuclear signals were counted under an Olympus
BX51 fluorescence microscope (Olympus America, Inc.), which yielded the
ratio of the copy numbers of the HER-2 gene to chromosome 17.
Validation of copy number changes from aCGH by real-time
polymerase chain reaction
The reaction was carried out in a total volume of 30 μl, containing 10 μl of
2×QuantiTect SYBR Green PCR master mix (Qiagen, Valencia, CA), 70 ng of
the genomic DNA, and a final concentration of 0.3 μM oligonucleotide primersas was suggested by the manufacturer. PCR was performed at 95°C for 15 min to
activate the HotstarTaq DNA polymerase and then for 40 cycles of amplification
at 95°C for 15 s, 58°C for 1 min, 72°C for 1 min on a PRISM 7700 Sequence
Detection System (Applied Biosystems, Foster City, CA). Reactions were
repeated twice for each gene and average Ct was obtained. The Ct of each gene
from normal and tumor tissue was normalized by subtracting the Ct of the Actin
gene (ΔCt) in normal tissue and tumor tissue, respectively. The fold change of
DNA copy changes was then obtained by the difference of normalized Ct values
of a gene in normal tissue and tumor tissue (ΔΔCt). After each run, dissociation
curves were drawn based on multicomponent data to show that a single
amplification product was generated from each reaction.
The following oligonucleotide primers were used for the amplification of
100- to 160-bp products: ACTG2 (Actin, gamma 2, smooth muscle, enteric,
Exon 8)_forward (F) (5′-GGAGTCCGCTGGAATTCATGAGACAA-3′), ACT-
G2_reverse (R) (5′-TGATCTCCTTCTGCATCCTGTCAGCAA-3′); ANKH
(Ankylosis, progressive homologue, Exon 13)_F (5′-TGCCTCACGAAAACC-
CAAAA-3′), ANKH_R (5′-CGATGAAGGGGGACAGGAGA-3′); PGM2
(Phosphoglucomutase 2, Exon 9)_F (5′-GAGGGTGTTTTCAGGCAATG-3′),
PGM2_R (5′-TAAGGCAATGGCCCGCAAGA-3′); GATA6 (GATA binding
protein 6, Exon 6)_F (5′-AGAGCACCAATCCCGAGAAC-3′), GATA6_R (5′-
TCGCACGGAGGACGTGACTT-3′); COPS6 (COP9 constitutive photomorpho-
genic homologue subunit 6, Exon 10)_F (5′-CCTGCTGGTGGCTCTGTCCT-3′),
COPS6_R (5′-GCAGGCAGCCTTGGACTTTG-3′); snd DMD (Dystrophin,
Exon 76)_F (5′-CCAGGCAGAGGCCAAAGTGA-3′) and DMD_R (5′-
CCGAAGTTTGACTGCCAACCA-3′).
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